MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
ER/PR Positive Breast Cancer
Triple Negative Breast Cancer
Metastatic Breast Cancer With Active Brain Metastasis

Interventions

DRUG: Ferumoxytol
DRUG: MM-398

Sponsor

Ipsen